Dr. Reddy’s, Prestige BioPharma ink pact on cancer drug

DRL gets rights to commercialise proposed trastuzumab biosimilar in select LatAm, S-E Asia markets.

Pharma major Dr. Reddy’s Laboratories has entered into a partnership with Prestige BioPharma under which it will get exclusive rights to supply and commercialise the Singapore firm’s proposed trastuzumab biosimilar in select Latin America and Southeast Asian countries.

Prestige BioPharma’s trastuzumab (HD201) is a proposed biosimilar to Roche’s Herceptin. It can be prescribed for treatment of HER2 positive breast and metastatic gastric cancer, the two companies said in a release on a binding agreement they have signed.